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Abstract: 
Based on a previously identified antileishmanial 6,8-dibromo-3-nitroimidazo[1,2-a]pyridine 
derivative, a Suzuki-Miyaura coupling reaction at position 8 of the scaffold was studied and optimized 
from a 8-bromo-6-chloro-3-nitroimidazo[1,2-a]pyridine substrate. Twenty-one original derivatives 
were prepared, screened in vitro for activity against L. infantum axenic amastigotes and T. brucei 
brucei trypomastigotes and evaluated for their cytotoxicity on the HepG2 human cell line. Thus, 7 
antileishmanial hit compounds were identified, displaying IC50 values in the 1.1 to 3 µM range. 
Compounds 13 and 23, the 2 most selective molecules (SI = >18 or >17) were additionally tested on 
both the promastigote and intramacrophage amastigote stages of L. donovani. The two molecules 
presented a good activity (IC50 = 1.2 to 1.3 µM) on the promastigote stage but only molecule 23, 
bearing a 4-pyridinyl substituent at position 8, was active on the intracellular amastigote stage, with a 
good IC50 value (2.3 µM), slightly lower than the one of miltefosine (IC50 = 4.3 µM). The antiparasitic 
screening also revealed 8 antitrypanosomal hit compounds, including 14 and 20, 2 very active (IC50 = 
0.04 to 0.16 µM) and selective (SI = >313 to 550) molecules toward T. brucei brucei, in comparison 
with drug-candidate fexinidazole (IC50 = 0.6 & SI >333) or reference drugs suramin and eflornithine 
(respective IC50 = 0.03 and 13.3 µM). Introducing an aryl moiety at position 8 of the scaffold quite 
significantly increased the antitrypanosomal activity of the pharmacophore. Antikinetoplastid 
molecules 13, 14, 20 and 23 were assessed for bioactivation by parasitic nitroreductases (either in L. 
donovani or in T. brucei brucei), using genetically modified parasite strains that over-express NTRs: 
all these molecules are substrates of type 1 nitroreductases (NTR1), such as those that are responsible 
for the bioactivation of fexinidazole. Reduction potentials measured for these 4 hit compounds were 
higher than that of fexinidazole (-0.83 V), ranging from -0.70 to -0.64 V. 
 
Highlights: 
A Suzuki-Miyaura reaction at position 8 of the imidazopyridine ring was studied 
21 derivatives were tested in vitro for their cytotoxicity and antiparasitic activity 
7 antileishmanial and 8 antitrypanosomal hit compounds were identified 
These nitroaromatic derivatives are bioactivated by type 1 nitroreductases 
 
Keywords:  
Imidazo[1,2-a]pyridine; nitroheterocycles; Suzuki-Miyaura cross-coupling reaction; Nitroreductases; 
Leishmania; Trypanosoma; In vitro activity, HepG2 cytotoxicity; SARs, redox potentials. 
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1. Introduction 
Trypanosomatids are a group of kinetoplastid parasites infecting mammalians. Among 
trypanosomatids, Leishmania and Trypanosoma are the two main genera responsible for 
human infections that mainly occur in the intertropical region. Although these parasitic 
infections are lethal if untreated, there are very f w efficacious, safe and affordable drugs 
available for treating infected patients with low income, living in developing countries. 
For this reason, the WHO classified trypanosomatid parasites among the infectious agents 
causing “neglected tropical diseases” [1, 2].  
The Leishmania parasites, mainly L. donovani and L. infantum, are responsible for 
leishmaniasis. Visceral leishmaniasis (VL) is the most severe clinical form with about 
300.000 new cases and 20.000 annual deaths annually, according to the WHO [3]. Briefly, 
the parasite is transmitted by the bite of a phlebotominae sandfly, as a flagellated motile 
promastigote which disseminates into the organism and penetrates into macrophages 
where it transforms into an amastigote stage, resistant to phagocytosis and multiplies, 
causing organ and tissue damages, leading to death [4].  
In the Trypanosoma genus, T. brucei (gambiense or rhodesiense) is one of the species 
responsible for human infections. It causes Human African Trypanosomiasis (HAT), also 
called sleeping sickness, affecting about 3.000 people annually, mainly in central Africa 
[5]. This parasitic disease occurs after the bite of a tsetse fly and develops in two clinical 
stages: a phase 1 peripheral haemolymphatic stage followed by a meningoencephalitic 
phase 2 in which the parasite crosses the blood-brain b rrier and invades the central 
nervous system, leading to death [6]. 
There are very few therapeutic options for treating VL in endemic areas: Antimony V 
derivatives are facing high resistance levels and are toxic molecules, pentamidine is also 
quite toxic and must be administered IV, amphotericin B is very active but also highly 
nephrotoxic, must be administered IV and is very expensive as a liposomal formulation 
and miltefosine, the only orally available drug, is teratogenic [7]. The available treatments 
against HAT carry similar disadvantages: pentamidine, melarsoprol, an arsenic derivative 
that is highly toxic, suramin which is only active on the phase 1 of the disease, and the 
eflornithine/nifurtimox combination for treating phase 2 [8, 9]. 
Looking at the molecules studied as antileishmanial drug candidates [9, 10], it must be 
noted that there is currently no novel chemical entity undergoing clinical trial against VL, 
at any stage [11], which is quite worrying. Regarding the antitrypanosomal pipeline, only 
acoziborole, a bore-containing molecule [9, 11] and fexinidazole, a nitroaromatic 
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compound, [9, 11, 12] are new chemical entities in cli ical development. At a pre-clinical 
stage of development, delamanid (a marketed antituberc losis treatment) is another 
nitroaromatic molecule displaying promising potential as an oral antileishmanial agent 
[13]. Thus, after several decades of abandonment, nitroaromatic derivatives are re-
emerging as key molecules to fight against critical nfectious diseases, displaying original 
mechanisms of action. As an antitrypanosomatid molecule, fexinidazole was first studied 
as an antileishmanial candidate [14]. It is a 5-nitroimidazole prodrug including a thioether 
group that is oxidized into an active sulfone metabolite (Figure 1). Fexinidazole did not 
show sufficient clinical efficacy when used orally as a single therapy for the treatment of 
VL in a phase 2 clinical trial. Nevertheless, fexinidazole demonstrated good efficacy in 
pre-clinical studies against both peripheral [15] and central [16] stages of HAT and has 
recently completed a phase 3 clinical trial against HAT [12]. 
 
Figure 1. Structure of drug candidate fexinidazole and its ac ive sulfone metabolite. 
 
The antitrypanosomatid mechanism of action of fexinidazole depends on its bioactivation by 
parasite enzymes called nitroreductases (NTRs). Including a flavin co-factor, these enzymes 
catalyze the 1- or 2-electron reduction of nitroaromatic derivatives into electrophilic nitroso 
and hydroxylamine metabolites that are cytotoxic, forming covalent adducts with nucleophilic 
entities such as cysteine residues or DNA bases [17]. Interestingly, mammalian cells do not 
possess NTRs, allowing very good antiparasitic selectivity for nitroaromatic compounds. In 
Leishmania, two nitroreductases have been characterized: an essential type 1 mitochondrial 
NTR1, catalyzing the 2-electron reduction of nitroaromatics [18, 19] and, recently, a type 2 
NTR2, catalyzing the 1-electron reduction of nitroaromatics [20]. In Trypanosoma, only one 
NTR1 was characterized [21]. Unfortunately, apart from their primary sequence, there is no 
structural data available for any of these parasitic NTRs. They have never been crystallized 
nor co-crystallized, which limits the rational medicinal chemistry approaches to the design of 
novel substrates of NTRs, as antitrypanosomatid canid tes. 
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The imidazo[1,2-a]pyridine ring is a well-known scaffold in pharmaceutical chemistry that 
has been extensively studied since the discovery of the hypnotic drug zolpidem (Ambien®, 
Stilnox®). Some imidazo[1,2-a]pyridine derivatives were reported as in vitro antileishmanial 
molecules [22] and our group previously reported the synthesis and biological evaluation of 3-
nitroimidazo[1,2-a]pyridines, active on both promastigote and intramacrophage amastigote 
stages of L. donovani [23]. Thus, a hit compound was identified (Figure 2), bearing 2 bromine 
atoms at positions 6 and 8, a nitro group at position 3 and a phenylsulfonylmethyl substituent 
at position 2 of the imidazo[1,2-a]pyridine ring. In this work, the nitro group appear d to be 
necessary for providing activity and the introduction of a bromine atom at position 8 of the 
scaffold appeared to increase antileishmanial activity [23]. 
 
Figure 2. Structure, in vitro antileishmanial activity and cytotoxicity of the previously 
identified hit molecule 6,8-dibromo-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine. 
 
From these encouraging preliminary results and based on a strategy that we previously 
applied to the antileishmanial pharmacomodulation of bicyclic nitroaromatic molecules using 
the Suzuki-Miyaura reaction [24], we decided to study the effect of introducing aryl moieties 
at position 8 of the 3-nitroimidazo[1,2-a]pyridine scaffold. Moreover, the new synthesized 
derivatives were not only studied for their antileishmanial activity, as done for the initial hit 
molecule, but also regarding their antitrypanosomal activity, to get a broader idea of the 
antiparasitic potential of the corresponding pharmacophore. 
 
2. Results and discussion 
Suzuki-Miyaura cross-coupling reactions at position 8 of the imidazo[1,2-a]pyridine ring 
were already reported [25]. However, when this ring is substituted by two bromine atoms at 
positions 6 and 8, the Suzuki-Miyaura coupling takes place at both positions [26]. To avoid 
this double coupling reaction and favor the selectiv  functionalization at position 8 while 
maintaining a halogen atom at position 6 (to preserve the antiparasitic pharmacophore), a new 
substrate was prepared (Scheme 1). Adopting a previously reported synthesis strategy [27, 
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28], 2-amino-5-chloropyridine was reacted with N-bromosuccinimide to afford 2-amino-3-
bromo-5-chloropyridine 1 which was cyclized into the corresponding imidazo[1,2-a]pyridine 
derivative 2 by reaction with 1,3-dichloroacetone. The nitration f molecule 2, in classical 
conditions, led to compound 3 which was engaged into a SN2 reaction with the sodium salt of 
benzenesulfinic acid to form molecule 4. Thus, an original substrate was prepared to conduct 
an antiparasitic pharmacomodulation study at position 8 via palladium-catalyzed coupling 
reactions. 
 
 
Scheme 1. Synthesis of substrate 4: a) NBS, acetonitrile, 80°C, 1 h, 71%; b) 1,3-
dichloroacetone, EtOH, 80°C, 96 h, 60%; c) HNO3, H2SO4, 0°C→RT, 1 h, 60%; d) Sodium 
benzenesulfinate, DMSO, RT, 3 h, 80%. 
Next, the Suzuki-Miyaura coupling reaction between 4 and phenylboronic acid was studied by 
varying several parameters such as nature and amount of catalyst, nature and amount of base, 
nature of solvent, reaction temperature and time, se king an efficient operating procedure 
(Table 1). The initial conditions were inspired from a previously reported protocol involving 
1.3 equiv. of phenylboronic acid, 10 mol% Pd(PPh3)4 and 3 equiv. of Na2CO3 in sealed tubes, 
under microwave (MW) heating [29]. The first studied parameter was the nature of the 
solvent (entries 1-10). By testing dioxane and dimethoxyethane (DME), it was rapidly noted 
that the total conversion of the substrate required to engage 5 equiv. of Na2CO3 (entries 3 and 
4). Neither tetrahydrofuran (THF) nor water (or water/organic solvent mixtures) led to the 
same reaction yield as DME (49%, entry 4). Then, several bases were studied (entries 11-16) 
and the best result was obtained with K2CO3 (64%, entry 16). The use of three other Pd-
containing catalysts (entries 17-19) did not show any improvement in reaction yield. When 
comparing entry 16 (best result) to conventional heting (entry 20) or to microwave heating at 
95°C (entry 21), it appeared that, with DME, the us of MW was favourable but increasing 
the reaction temperature was not. Finally, DME was replaced by THF and a very efficient 
procedure (90% yield) was achieved by heating at 120°C in a sealed tube under MW for only 
1 h (entry 25). In these efficient conditions, decreasing the amount of catalyst to 0.05 equiv. 
led to a poor reaction yield (36%, entry 26). To validate the operating conditions determined 
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with phenylboronic acid, 2 other phenylboronic acid derivatives were engaged in the same 
reaction (entries 27-28), leading to comparable yields (84 and 87%) after 2 h. 
Table 1. Optimization of the Suzuki-Miyaura cross-coupling reaction between substrate 4 and 
phenylboronic acid. 
 
Entry Reactant 
(1.3 equiv.) 
Solvent Base Catalyst Temp (°C) Time 
(h) 
Yielda 
(%) 
1 Ph-B(OH)2 Dioxane Na2CO3, 3 equiv. Pd(PPh3)4; 0.1 equiv. 110 24 -b 
2 Ph-B(OH)2 DME Na2CO3, 3 equiv. Pd(PPh3)4; 0.1 equiv. 85, MW 2 -b 
3 Ph-B(OH)2 Dioxane Na2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 110 24 47 
4 Ph-B(OH)2 DME Na2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 85, MW 2 49 
5 Ph-B(OH)2 THF Na2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 70, MW 3 -b 
6 Ph-B(OH)2 Water Na2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 100 24 -b 
7 Ph-B(OH)2 Water + TBAB Na2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 100, MW 3 -b 
8 Ph-B(OH)2 Water/EtOH (8:2) Na2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 90, MW 3 -b 
9 Ph-B(OH)2 Water/EtOH (5:5) Na2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 90, MW 3 40 
10 Ph-B(OH)2 DME/Water (9:1) Na2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 85, MW 3 -b 
11 Ph-B(OH)2 DME Cs2CO3, 3 equiv. Pd(PPh3)4; 0.1 equiv. 85, MW 1.5 25 
12 Ph-B(OH)2 DME K3PO4, 5 equiv. Pd(PPh3)4; 0.1 equiv. 85, MW 3 20 
13 Ph-B(OH)2 DME CsF, 5 equiv. Pd(PPh3)4; 0.1 equiv. 85, MW 3 -b 
14 Ph-B(OH)2 DME K2CO3, 3 equiv. Pd(PPh3)4; 0.1 equiv. 85, MW 3 -b 
15 Ph-B(OH)2 DME K2CO3, 4 equiv. Pd(PPh3)4; 0.1 equiv. 85, MW 3 -b 
16 Ph-B(OH)2 DME K2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 85, MW 3 64 
17 Ph-B(OH)2 DME K2CO3, 5 equiv. Pd(dppf)Cl2; 0.1 equiv. 85, MW 3 53 
18 Ph-B(OH)2 DME K2CO3, 5 equiv. PdCl2(PPh3)2; 0.1 equiv. 85, MW 3 51 
19 Ph-B(OH)2 DME K2CO3, 5 equiv. Pd(OAc)2; 0.1 equiv. 85, MW 3 58 
20 Ph-B(OH)2 DME K2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 85 6 49 
21 Ph-B(OH)2 DME K2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 95, MW 2 58 
22 Ph-B(OH)2 THF K2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 70 36 73 
23 Ph-B(OH)2 THF K2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 70, MW 3 -b 
24 Ph-B(OH)2 THF K2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 90, MW 5 90 
25 Ph-B(OH)2 THF K 2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 120, MW 1 90 
26 Ph-B(OH)2 THF K2CO3, 5 equiv. Pd(PPh3)4; 0.05 equiv. 120, MW 1 36 
27 4-CH3O-Ph- B(OH)2 THF K2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 120, MW 2 84 
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28 4-CF3-Ph-B(OH)2 THF K2CO3, 5 equiv. Pd(PPh3)4; 0.1 equiv. 120, MW 1 87 
aThe reaction yield was calculated form the product isolated after purification by chromatography column. 
bOnly partial conversion of starting material was oberved on TLC 
In bold: Best reaction conditions 
As presented in Scheme 2, after optimizing the operating procedure, the reaction was 
extended to 20 other aryl- or heteroarylboronic acids, to synthesize a small library of novel 
derivatives bearing various aryl groups (substituted phenyl, thiophene, furan or pyridine) at 
position 8 of the imidazopyridine scaffold. The reaction yields varied from 90% 
(phenylboronic acid) to 41% (2-CF3-phenylboronic acid) and were generally lower when 
using pyridinylboronic (51-53%) or furanylboronic (53%) acids. The X-ray structures of 
substrate 4 and coupling product 23 are presented in Figure 3. 
 
e
N
Cl
N O2S
Br
NO2
4 (1 equiv.)
B
Ar OH
OH
N
Cl
N O2S
Ar
NO2
5 - 25
(1.3 equiv.)  
Scheme 2. General procedure for the Suzuki-Miyaura cross-coupling reaction between 
imidazo[1,2-a]pyridine derivative 4 and various aryl- or heteroarylboronic acids using the 
optimized protocol: e) 0.1 equiv. of Pd(PPh3)4, 5 equiv. of K2CO3, THF in sealed tube, 120°C, 
MW, 30 min to 2 h, 41% to 90% yield. 
 
  
  
Figure 3. X-ray structures of compounds 4 (left) and 14 (right). 
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All synthesized compounds were tested in vitro for their cytotoxicity on the HepG2 human 
cell line and compared to a cytotoxic reference drug: doxorubicin (Table 2). Out of the 21 
tested compounds, 8 molecules (6, 7, 9, 17, 18, 19, 24 and 25) could not be evaluated properly 
because of a lack of solubility in the culture medium. Thus, in comparison with the initial 8-
brominated hit-compound (cLogP = 3.4), solubility in the culture medium was improved only 
when introducing a 4-pyridinyl or a 2-(hydroxymethyl)phenyl substituent at position 8 of the 
scaffold. Regarding the link between solubility in the aqueous culture medium and cLogP 
values in the studied series, it can be noted that all poorly soluble compounds (apart 25) were 
the ones displaying cLogP values between 3.9 and 5.0 whereas the 2 most soluble compounds 
(14 and 23) were the ones displaying cLogP values of 3.4 and 2.9, respectively. Compound 12 
was the most cytotoxic (CC50 = 13 µM), whereas compound 14 was the least cytotoxic (CC50 
= 88 µM). Then, 13 molecules were screened in vitro for their activity against L. infantum 
axenic amastigotes and compared to 3 reference drugs (or drug candidate): amphotericin B, 
miltefosine and fexinidazole (Table 2). Seven molecul s (5, 13, 15, 20, 21, 22, 23) appeared 
as new antileishmanial hit compounds by displaying good IC50 values (1.1 to 3 µM), close to 
the ones of miltefosine (0.8 µM) and fexinidazole (3.4 µM), together with selectivity index 
values above 10. Regarding antitrypanosomal activity, molecules were screened on the 
trypomastigote stage of T. brucei brucei and compared to 3 antitrypanosomal drugs (or drug 
candidate): eflornithine, suramin and fexinidazole (Table 2). Eight molecules (10, 12, 13, 14, 
20, 21, 22, 23) were considered as good antitrypanosomal hit compounds, presenting low IC50 
values (0.04 to 0.25 µM), in comparison with all refe nce drugs, associated to high 
selectivity index values, ranging from >136 to 550. With respect to the initial hit compound 
(IC50 = 2.9 µM), it is important to note that introducing a phenyl or a pyridinyl group at 
position 8 of the pharmacophore strongly increased the antitrypanosomal activity. By 
combining all parameters, 5 molecules bearing a 3-(hydroxymethyl)phenyl (13), a CF3-
substituted phenyl (20, 21) or pyridinyl (22, 23) moiety at position 8 of the imidazo[1,2-
a]pyridine ring, were the ones displaying a global antikinetoplastid profile. 
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Table 2. In vitro antileishmanial (L. infantum) and antitrypanosomal screening and 
cytotoxicity of synthesized imidazo[1,2-a]pyridine derivatives (5-25).  
 
Compd R- 
CC50 HepG2  
(µM) 
IC 50 L. infantum 
axenic 
amastigotes 
(µM) 
Selectivity 
Index (SI) 
Leishmaniaf 
IC 50 T. brucei 
brucei 
trypomastigote
s (µM) 
Selectivity 
Index (SI) 
Trypanosomag 
cLogPh 
5 Ph- >15.6d 1.6 ± 0.6 >10 0.61 ± 0.2 >25.6 4.1 
6 4-Cl-Ph- >3.9d - - - - 4.8 
7 4-CH3O-Ph- >3.9d - - - - 4.0 
8 4-((C2H5)2N)-Ph- >15.6d 2.5 ± 0.5 >6.2 0.43 ± 0.06 >36.3 5.0 
9 4-CN-Ph- >3.9d - - - - 4.0 
10 4-CHO-Ph- >31.2d 3.8 ± 0.3 >8.2 0.08 ± 0.02 >390 3.9 
11 4-OH-Ph- >12.5d 3.0 ± 0.8 >4.2 0.41 ± 0.08 >30.5 3.8 
12 4-CH2OH-Ph- 13.1 ± 6.0 1.5 ± 0.4 8.7 0.09 ± 0.03 145.6 3.4 
13 3-CH2OH-Ph- >25d 1.4 ± 0.2 >17.9 0.15 ± 0.03 >166.7 3.4 
14 2-CH2OH-Ph- 88 ± 32.0 >10e <8.8 0.16 ± 0.03 550 3.4 
15 4-F-Ph- >15.6d 1.3 ± 0.2 >12 0.31 ± 0.2 >50.3 4.3 
16 3-F-Ph- >12.5d 1.7 ± 0.5 >7.4 0.2 ± 0.1 >62.5 4.3 
17 2-F-Ph- >3.9d - - - - 4.3 
18 2,4-F-Ph- >7.8d - - - - 4.4 
19 4-CF3-Ph- >3.9d - - - - 5.0 
20 3-CF3-Ph- >12.5d 1.1 ± 0.3 >11.4 0.04 ± 0.01 >312.5 5.0 
21 2-CF3-Ph- 22.7 ± 3.9  1.6 ± 0.4 14.2 0.07 ± 0.02 324.3 5.0 
22 Pyridin-3-yl- >31.3d 2 ± 0.6 >15.7 0.23 ± 0.01 >136.1 2.9 
23 Pyridin-4-yl- >50d 3 ± 0.8 >16.7 0.25 ± 0.01 >200 2.9 
24 Thiophen-2-yl- >3.9d - - - - 3.9 
25 Furan-2-yl- >3.9d - - - - 3.2 
Initial hit molecule >31d 4.4 ± 0.8 >7.1 2.9 ± 0.5 >10.7 3.4 
Doxorubicina 0.2 ± 0.02 - - - -  
Amphotericin Bb 8.8 ± 0.3 0.06 ± 0.001 146.7 - -  
Miltefosineb 85 ± 8.8 0.8 ± 0.2 106.3 - -  
Fexinidazoleb,c >200e 3.4 ± 0.8 >58.8 0.6 ± 0.2 >333  
Suraminc >100e - - 0.03 ± 0.009 >3333  
Eflornithinec >100e - - 13.3 ± 2.1 >7.5  
a Doxorubicin was used as a cytotoxic reference drug
b Amphotericin B, Miltefosine and Fexinidazole were used as antileishmanial reference drugs 
c Fexinidazole, Suramin and Eflornithine were used as antitrypanosomal reference drugs 
d The product could not be tested at higher concentrations in aqueous medium 
e The CC50 or IC50 value was not reached at the highest tested concentratio  
f SI = CC50 HepG2 / IC50 L. infantum 
g SI = CC50 HepG2 / IC50 T. brucei brucei 
h Weighted LogP were computed with MARVIN® software (ChemAxon) 
 
To deeper evaluate the antileishmanial potential of m lecules 13 and 23 (molecules with 
suitable aqueous solubility, low cytotoxicity, good activity and highest selectivity indices), an 
in vitro evaluation toward both the promastigote and the intramacrophage amastigote stage of 
L. donovani was carried out, after evaluating their cytotoxicity on the THP1 macrophage cell 
line (Table 3). The results showed that molecule 13, containing a 3-(hydroxymethyl)phenyl 
moiety, was active on the promastigote stage but was not on the intramacrophage amastigote 
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one whereas molecule 23, presenting a 4-pyridinyl moiety, was active on both stages. 
Considering the key activity toward the intramacrophage amastigote stage, molecule 23 was 
not only more active (IC50 = 2.3 µM) than the initial hit compound (IC50 = 5.5 µM), but was 
also slightly more active and selective (SI > 22) than miltefosine (IC50 = 4.3 µM, SI = 20) and 
as selective as amphotericin B (SI = 22). Neverthless, the aqueous solubility of hit molecule 
23 remains to improve. Fexinidazole was not active in vitro toward the intramacrophage 
amastigote stage of L. donovani; only its sulfone metabolite is able to display intracellular 
activity [14-16]. 
 
Table 3. In vitro antileishmanial profile of hit compounds 13 and 23. 
N° Structure 
IC 50 L. donovani 
promastigotes 
(µM) 
& SIHepG2 
IC 50 L. donovani 
intramacrophage 
amastigotes 
(µM) 
& SIHepG2 
IC 50 L. infantum 
axenic 
amastigotes 
(µM) 
& SIHepG2 
CC50 
HepG2 
(µM) 
CC50 
THP1 
(µM) 
13 
 
1.3 ±0.2 
>19.2 
>10d 
- 
1.4 ±0.2 
>17.9 
>25c >15c 
23 
 
1.2 ±0.4 
>41.7 
2.3 ±0.6 
>21.7 
3.0 ±0.8 
>16.7 
>50c >25c 
 
Initial Hit  
1.8 ±0.8 
>17.2 
5.5 ±0.2 
>5.6 
4.4 ±0.8 
>7.0 
>31c >25c 
Doxorubicina - - - 0.2+/-0.02 1.4 +/-0.5 
Fexinidazoleb 
1.2 ±0.2 
> 166.7 
>50d 
- 
3.4 ±0.8 
>58.8 
>200d >62.5c 
Miltefosineb 
3.1 ±0.2 
27.4 
4.3 ±1.7 
19.8 
0.8 ±0.2 
106.3 
85 +/-8.8 >40d 
Amphotericin Bb 
0.07 ±0.01 
125.7 
0.4 ±0.01 
22 
0.06 ±0.001 
146.7 
8.8 3.6 +/-0.7 
a Doxorubicin was used as a cytotoxic reference drug
b Amphotericin B, Miltefosine and Fexinidazole were used as antileishmanial reference drugs 
c The product could not be tested at higher concentrations in aqueous medium 
d The CC50 or IC50 value was not reached at the highest tested concentratio  
 
To investigate the antiparasitic mechanism of action of these new nitrated molecules, we 
hypothesized that they could be substrates of kinetoplastid nitroreductases. This hypothesis 
was tested by comparing the IC50 values measured on wild-type parasite strains withthe ones 
measured on recombinant parasite strains overexpressing a nitroreductase (Table 4). Thus, the 
activities of molecules 13 and 23 were determined in parallel on a L. donovani wild-type 
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strain (promastigote stage) and on two L. donovani strains overexpressing either NTR1 [19] 
or NTR2 [20]. As noted with the initial hit molecule, compounds 13 and 23 are selectively 
bioactivated by L. donovani NTR1 as their IC50 values are 20 to 40 times lower on the NTR1 
overexpressing strain than on the wild type one. The same approach was followed with 
compounds 14 and 20. Their activities toward a wild type strain of T. brucei brucei 
(trypomastigote stage) and a recombinant strain overexpressing NTR1 [21] were compared 
(Table 4). Like with nifurtimox, used as a referenc drug, the tested molecules were more 
active (two-fold increase in activity) on the strain overexpressing NTR1. Interestingly, these 
molecules, especially compound 20, were much more active than nifurtimox toward T. brucei 
brucei. It can then be concluded that molecules 13, 14, 20 and 23 are novel antikinetoplastid 
nitroaromatic compounds that are bioactivated by type 1 nitroreductases (NTR1), the same 
enzymes as the ones involved in the mechanism of action of fexinidazole by generating 
cytotoxic reduction metabolites [14]. 
 
Table 4. 8-Aryl-3-nitroimidazo[1,2-a]pyridines are bioactivated by kinetoplastid type 1 
nitroreductases (NTR1) 
 
L. donovani promastigotes IC50 (µM) 
Wild-type NTR1OE NTR2OE 
13 1.4 ±0.07 0.07 ±0.003 1.9 ±0.04 
23 1.5 ±0.05 0.04 ±0.009 2.0 ±0.2 
Initial hit molecule 1.9 ± 0.08 0.07 ± 0.002 3.0 ± 0.08 
 
T. brucei brucei trypomastigotes IC50 (µM) 
Wild-type NTR1OE 
14 0.39 ±0.07 0.19 ± 0.019 
20 0.09 ± 0.002 0.04 ± 0.001 
Nifurtimox 1.87 ± 0.05 0.6 ± 0.05 
 
Finally, an electrochemical study was done by measuring the reduction potentials of 7 
molecules belonging to the studied series, using cyclic voltammetry, and comparing them to 
the one of fexinidazole (Table 5). For all tested molecules, a reversible single electron 
reduction was observed, corresponding to the formation of a nitro radical anion (see 
supplementary data). The redox potentials of all molecules belonging to the 3-
nitroimidazo[1,2-a]pyridine series ranged from -0.7 to -0.6 V and were higher than that of 
fexinidazole (E° = -0.83 V). When comparing brominated molecule 4 to the Suzuki-Miyaura 
coupling product 5, bearing a phenyl moiety, it can be noted that the p nyl ring slightly 
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reduces the E° value (-0.69 versus -0.65 V). Introducing electron-donating (-CH2OH) or 
electron-withdrawing (-CF3) groups on the phenyl ring at position 2 or 3 has a very limited 
influence on the redox potential (+/- 0.01 or 0.02 V), whereas substituting a 4-pyridinyl 
moiety to the phenyl ring slightly increases the redox potential (-0.64 versus -0.69 V). 
Comparison of molecule 4 (8-bromo-6-chloro) to the initial hit (6,8-dibromo), showed that 
substituting a chlorine atom for a bromine atom at position 6 of the imidazo[1,2-a]pyridine 
ring decreases the E° value from -0.59 to -0.65 V. These results indicate that, in the studied 
series, it is possible to improve the antikinetoplastid activity while significantly decreasing the 
redox potential values from -0.59 V (initial hit) to -0.70 V (13 and 14), this last value 
remaining compatible with kinetoplastid NTR1 enzymatic capabilities. Starting from the 
initial hit compound, this decrease in E° value was achieved by introducing a chlorine atom at 
position 6 of the 3-nitroimidazo[1,2-a]pyridine scaffold and by introducing a phenyl group at 
position 8. 
Table 5. Reduction potential modulation in the studied series 
 
Compd R- E° (V) 
4 
 
-0.65 
5 
 
-0.69 
13 
 
-0.70 
14 
 
-0.70 
20 
 
-0.67 
23 
 
-0.64 
 
Initial Hit 
-0.59 
Fexinidazole -0.83 
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Cyclic voltammetry conditions: DMSO/TBAPF6, SCE/GC, 1 electron reversible reduction, values ar  given in volt and are corrected toward 
NHE 
 
Katsuno and co-workers [30] proposed a list of criteria to define antileishmanial and 
antitrypanosomal hit compounds, including original structure, easy synthesis (up to 5 reaction 
steps), IC50 < 10 µM (both on the promastigote and intramacrophage amastigote stages for 
Leishmania) and selectivity index > 10 (in comparison with mammalian cells). Of the 21 
tested molecules, compound 23 meets all these criteria for an antileishmanial moecule and 13 
compounds meet the same criteria for antitrypanosomal molecules. 
 
3. Conclusion 
 
To design novel antitrypanosomatid molecules, a selective Suzuki-Miyaura coupling reaction 
was developed at position 8 of a 6,8-dihalogeno-3-nitroimidazo[1,2-a]pyridine 
antileishmanial pharmacophore which was previously identified. A series of 21 new 
derivatives was prepared and screened in vitro toward Leishmania and Trypanosoma, 
highlighting 1 antileishmanial (molecule 23) and several antitrypanosomal (including 14 and 
20) hit compounds with high activities (0.04 µM < IC50 < 3 µM) and good to excellent 
selectivity (10 < SI < 550) versus the HepG2 human cell line. Replacing the bromine atom at 
position 8 by aryl moieties particularly improved the antitrypanosomal activity. All 
derivatives appeared to be metabolized by type 1 nitroreductases (NTR1) in both Leishmania 
and Trypanosoma; their mechanism of action is therefore probably analogous to that of drug 
candidate fexinidazole. Indeed, the redox potentials of these new hit compounds were lower 
than that of the previously identified and less active hit molecule (-0.59 V), ranging from -0.7 
to -0.6 V. Although a slight improvement in the aqueo s solubility of this promising chemical 
series was achieved by introducing a 4-pyridinyl moiety, water solubility remains to be 
improved in order to achieve optimal properties forinitiating in vivo studies on mouse 
models. 
 
Experimental Section 
 
Chemistry 
 
 General procedures 
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All commercially available solvents and reagents were purchased from commercial suppliers 
(Fluorochem or Sigma Aldrich) and used without furthe  purification. Melting points were 
determined in open capillary tubes with a Büchi apparatus and are uncorrected. 1H and 13C 
NMR spectra were determined on a Brucker Avance 200, 3  or 400 MHz instrument at the 
Faculté de Pharmacie de Marseille, Faculté des Sciences de St Jérôme (Marseille) and at the 
Laboratoire de Chimie de Coordination of Toulouse. Chemical shifts are given in δ values 
referenced to the solvent and using tetramethylsilane (TMS) as an internal standard. High 
resolution mass spectra were recorded on a QStar Eli e mass spectrometer at the Spectropôle 
department of the Faculté des Sciences de St Jérôme. Silica Gel 60 (Merk 70–230) was used 
for column chromatography. TLC was performed on aluminium plates coated with silica gel 
60F-254 (Merk) in an appropriate eluent. Visualisation was made with ultraviolet light (234 
nm). Progress of the reactions and purity of the synthesized compounds were checked with 
LC-MS analyses which were realized at the Faculté de Pharmacie de Marseille on a Thermo 
Scientific Accela High Speed LC System® coupled with a single quadrupole mass 
spectrometer Thermo MSQ Plus®. The RP-HPLC column used is a Thermo Hypersil Gold® 
50 x 2.1 mm (C13 bounded), with particles of 1.9 µM diameter. The volume of sample 
injected on the column was 1 µL. The chromatographic analysis, total duration of 8 min, is 
made with the following gradient of solvents: t = 0 min, water/methanol 50/50; 0 < t < 4 min, 
linear increase in the proportion of water to a water/methanol ratio of 95/5; 4 < t < 6 min, 
water/methanol 95/5; 6 < t < 7 min, linear decrease in the proportion of water to return to a 
ratio water/methanol of 50/50; 6 < t < 7 min, water/methanol 50/50. The water used was 
buffered with 5 mM ammonium acetate. The microwave reactions were performed in sealed 
vials, using a Biotage Initiator or CEM Discover SP-D microwave oven. 
 
 Synthesis 
3-Bromo-5-chloropyridin-2-amine (1) [31]: To a solution of 5-chloropyridin-2-amine (10 g, 
77.8 mmol, 1 equiv.) in acetonitrile (150 mL), N-bromosuccinimide (13.8 g, 77.8 mmol, 1 
equiv.) was added. The reaction mixture was stirred an  refluxed for 1 h. Then the solvent 
was evaporated in vacuo. Compound 1 was obtained, after purification by chromatography on 
silica gel (eluent: dichloromethane–ethyl acetate 9:1) and recrystallization from propan-2-ol 
as a pale beige solid in 71% yield. mp: 82 °C, Lit.: 83-84 °C; 1H NMR (400 MHz, 
[D6]DMSO) δ: 6.43 (2H, s), 7.88 (1H, d, J = 2.2 Hz), 7.96 (1H, d, J = 2.2 Hz), 
13C NMR (100 
MHz, [D6]DMSO) δ: 103.0 (C), 117.1 (C), 139.0 (CH), 145.0 (CH), 155.3 (C); MS ESI
+ 
(m/z): 207.27/209.32 [M+H]+. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
8-Bromo-6-chloro-2-chloromethylimidazo[1,2-a]pyridine  (2): To a solution of 3-bromo-5-
chloropyridin-2-amine 1 (10 g, 48.2 mmol, 1 equiv.) in ethanol (150 mL), 1,3-dichloroacetone 
(6.68 g, 53 mmol, 1.1 equiv.) was added. The reaction mixture was stirred and heated under 
reflux for 96 h. The solvent was then evaporated in vacuo. Compound 2 was obtained, after 
purification by chromatography on silica gel (eluent: dichloromethane–ethyl acetate 9:1) and 
recrystallization from diethyl ether as a white solid in 60% yield. mp: 161 °C; 1H NMR (400 
MHz, CDCl3) δ: 4.78 (2H, s), 7.47 (1H, d, J = 1.7 Hz), 7.70 (1H, br s), 8.12 (1H, d, J = 1.7 
Hz); 13C NMR (100 MHz, CDCl3) δ: 39.3 (CH2), 111.9 (C), 113.2 (CH), 120.5 (C), 123.1 
(CH), 128.7 (CH), 141.9 (C), 145.1 (C); MS ESI+ (m/z): 280.99/282.97 [M+H]+; HRMS 
(+ESI): 280.9064 [M + H]+; Calcd for C8H5N2BrCl2: 280.9062. 
 
8-Bromo-6-chloro-2-chloromethyl-3-nitroimidazo[1,2-a]pyridine  (3): To a solution of 8-
bromo-6-chloro-2-chloromethylimidazo[1,2-a]pyridine 2 (5 g, 18 mmol, 1 equiv.) in 
concentrated sulfuric acid (50 mL) cooled by an ice-water bath, nitric acid 65% (5 mL, 0.11 
mol, 6 equiv.) was added. The reaction mixture was stirred for 1 h at room temperature. Then, 
the mixture was slowly poured into an ice-water mixture and the desired product precipitated. 
The yellow solid was collected by filtration, dried under reduced pressure and recrystallized 
from propan-2-ol to give the expected product 3 in 60% yield. mp 165 °C; 1H NMR (400 
MHz, CDCl3) δ: 5.09 (2H, s), 7.92 (1H, d, J = 1.8 Hz), 9.49 (1H, d, J = 1.8 Hz); 
13C NMR 
(100 MHz, CDCl3) δ: 38.3 (CH2), 113.3 (C), 124.8 (CH), 125.3 (C), 129.9 (C), 134.2 (CH), 
141.0 (C), 147.7 (C); MS ESI+ (m/z): 324.00/325.93 [M+H]+; HRMS (+ESI): 323.8938 [M + 
H]+; Calcd for C8H4N3O2BrCl2: 323.8937. 
 
8-Bromo-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine (4): To a 
solution of 8-bromo-6-chloro-2-chloromethyl-3-nitroimidazo[1,2-a]pyridine 3 (5 g, 15.39 
mmol, 1 equiv.) in dimethylsulfoxide (150 mL), sodium benzenesulfinate (7.58 g, 46.17 
mmol, 3 equiv.) was added. The reaction mixture wasstirred for 3 h at room temperature. The 
reaction mixture was then slowly poured into an ice-water mixture, making the desired 
product precipitate. The pale orange solid was colle ted by filtration, dried under reduced 
pressure and recrystallized from acetonitrile to give the expected product 4 in 80% yield. mp 
196 °C; 1H NMR (400 MHz, CDCl3) δ: 5.14 (2H, s), 7.52–7.56 (2H, m), 7.66–7.69 (1H, m)  
7.84–7.89 (3H, m), 9.42 (1H, br s); 13C NMR (100 MHz, CDCl3) δ: 56.8 (CH2), 113.3 (C), 
124.8 (CH), 125.4 (C), 128.6 (2CH), 129.4 (2CH), 131.8 (C), 134.2 (CH), 134.4 (CH), 139.2 
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(C), 139.8 (C), 141.1 (C); MS ESI+ (m/z): 429.84/431.82 [M+H]+. HRMS (+ESI): 431.9236 
[M + H]+; Calcd for C14H9N3O4SClBr: 431.9236. 
 
General procedure for the preparation of 8-arylimidazo[1,2-a]pyridine derivatives (5 to 
25): A mixture of 8-bromo-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 
(400 mg, 1 equiv.), tetrakis(triphenylphosphine)palladium(0) (0.1 equiv., 107.3 mg), 
potassium carbonate (5 equiv., 642 mg), and appropriate boronic acid (1.3 equiv.) in THF (15 
mL) under N2 atmosphere was heated at 120 °C under microwave irradiation until complete 
disappearance of the starting material (as monitored by LC/MS or TLC). Water was then 
added and the mixture was extracted three times with dichloromethane. The organic layer was 
washed three times with water, dried over MgSO4, filtered and evaporated. The crude residue 
was purified by column chromatography on silica gel and recrystallized from the appropriate 
solvent, affording compounds 5 to 25. 
 
6-Chloro-3-nitro-8-phenyl-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine (5):  
Compound 5 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 6.5/3/0.5) and recrystallization from acetonitrile 
as a yellow solid in 90% yield (0.36 g). mp 201 °C.1H NMR (400 MHz, CDCl3) δ: 5.18 (s, 
2H), 7.45–7.49 (m, 3H), 7.52–7.56 (m, 2H), 7.68–7.72 (m, 4H), 7.87–7.89 (m, 2H), 9.47 (d, J 
= 1.9 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ: 56.7 (CH2), 124.3 (CH), 126.2 (C), 128.7 
(2CH), 129.0 (2CH), 129.4 (2CH), 129.5 (2CH), 130.0 (CH), 130.4 (CH), 131.2 (C), 132.0 
(C), 133.1 (C), 134.1 (CH), 139.4 (C), 139.7 (C), 141.9 (C). MS ESI+ (m/z): 427.98/429.87 
[M+H] +. HRMS (+ESI): 428.0464 [M + H]+. Calcd for C20H14N3O4SCl: 428.0466. 
 
6-Chloro-8-(4-chlorophenyl)-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 
(6): Compound 6 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 6.5/3/0.5) as a pale yellow solid in 74% yield 
(0.32 g). mp 250 °C; 1H NMR (400 MHz, [D6]DMSO) δ: 5.29 (s, 2H), 7.48–7.50 (m, 2H), 
7.62–7.69 (m, 4H), 7.80–7.87 (m, 3H), 8.13 (d, J = 1.7 Hz, 1H), 9.37 (d, J = 1.7 Hz, 1H); 13C 
NMR (100 MHz, [D6]DMSO) δ: 55.6 (CH2), 124.4 (C), 125.1 (CH), 128.3 (2CH), 128.4 
(2CH), 128.8 (C), 129.4 (2CH), 130.4 (CH), 131.2 (2CH), 131.7 (C), 132.6 (C), 134.2 (CH), 
134.4 (C), 138.6 (C), 139.4 (C), 140.9 (C); MS ESI+ (m/z): 461.89/463.84 [M+H]+; HRMS 
(+ESI): 462.0074 [M + H]+; Calcd for C20H13N3O4SCl2: 462.0077. 
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6-Chloro-8-(4-methoxyphenyl)-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 
(7): Compound 7 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 5.5/4/0.5) and recrystallization from acetonitrile 
as a yellow solid in 84% yield (0.36 g). mp 246 °C;1H NMR (400 MHz, [D6]DMSO) δ: 3.85 
(s, 3H), 5.30 (s, 2H), 6.97 (d, J = 8.9 Hz, 2H), 7.63–7.69 (m, 4H), 7.82–7.86 (m, 3H), 8.4 (d, J 
= 1.9 Hz, 1H), 9.31 (d, J = 1.9 Hz, 1H); 13C NMR (100 MHz, [D6]DMSO) δ: 55.3 (CH3), 55.6 
(CH2), 113.8 (2CH), 123.9 (CH), 124.5 (C), 125.0 (C), 128.3 (2CH), 129.2 (CH), 129.3 
(2CH), 129.8 (C), 130.8 (2CH), 131.0 (C), 134.1 (CH), 138.7 (C), 139.2 (C), 141.1 (C), 160.2 
(C); MS ESI+ (m/z): 457.94/459.96 [M+H]+; HRMS (+ESI): 458.0569 [M + H]+; Calcd for 
C21H16N3O5SCl: 458.0572. 
 
4-(6-Chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridin-8-yl)- N,N-
diethylaniline (8): Compound 8 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 4.5/5/0.5) and recrystallization from acetonitrile 
as a red solid in 50% yield (0.23 g). mp 188 °C; 1H NMR (400 MHz, [D6]DMSO) δ: 1.14 (t, J 
= 6 Hz, 6H), 3.40–3.44 (m, 4H), 5.30 (s, 2H), 6.62 (d, J = 8.2 Hz, 2H), 7.61–7.68 (m, 4H), 
7.80–7.94 (m, 4H), 9.20 (s, 1H); 13C NMR (100 MHz, [D6]DMSO) δ: 12.5 (2CH3), 43.7 
(2CH2), 55.7 (CH2), 110.8 (2CH), 118.5 (C), 122.4 (CH), 124.7 (C), 127.2 (CH), 128.3 
(2CH), 129.4 (2CH), 130.4 (C), 130.5 (2CH), 130.8 (C), 134.0 (CH), 138.8 (C), 138.9 (C), 
141.1 (C), 148.1 (C); MS ESI+ (m/z): 498.81/500.87 [M+H]+; HRMS (+ESI): 499.1204 [M + 
H]+; Calcd for C24H23N4O4SCl: 499.1201. 
 
4-(6-Chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridin-8-yl)benzonitrile (9):  
Compound 9 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 5.5/3.5/1) and recrystallization from acetonitrile 
as a beige solid in 65% yield (0.27 g). mp 258 °C; 1H NMR (400 MHz, [D6]DMSO) δ: 5.30 
(s, 2H), 7.63–7.67 (m, 2H), 7.81–7.86 (m, 4H), 7.88–7.92 (m, 3H), 8.22 (s, 1H), 9.42 (s, 1H); 
13C NMR (100 MHz, [D6]DMSO) δ: 55.5 (CH2), 111.9 (C), 118.5 (C), 124.3 (C), 125.8 (CH), 
128.1 (C), 128.4 (2CH), 129.3 (2CH), 130.2 (2CH), 131.2 (CH), 131.8 (C), 132.1 (2CH), 
134.2 (CH), 137.4 (C), 138.5 (C), 139.4 (C), 140.8 (C); MS ESI+ (m/z): 452.84/4754.94 
[M+H] +. HRMS (+ESI): 453.0418 [M + H]+; Calcd for C21H13N4O4SCl: 453.0419. 
 
4-(6-Chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridin-8-yl)benzaldehyde 
(10): Compound 10 was obtained after purification by chromatography (eluent: 
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dichloromethane/cyclohexane/diethyl ether 5/4/1) and recrystallization from acetonitrile as a 
yellow solid in 62% yield (0.26 g). mp 221 °C; 1H NMR (400 MHz, [D6]DMSO) δ: 5.31 (s, 
2H), 7.64–7.67 (m, 2H), 7.82–7.87 (m, 5H), 7.93–7.95 (m, 2H), 8.22 (d, J = 1.8 Hz, 1H), 9.41 
(d, J = 1.8 Hz, 1H), 10.10 (s, 1H); 13C NMR (100 MHz, [D6]DMSO) δ: 55.6 (CH2), 124.3 (C), 
125.6 (CH), 128.4 (2CH), 128.8 (C), 129.2 (2CH), 129.3 (2CH), 130.1 (2CH), 131.0 (CH), 
131.1 (C), 134.1 (CH), 136.2 (C), 138.4 (C), 138.6 (C), 139.4 (C), 140.9 (C), 192.8 (C); MS 
ESI+ (m/z): 455.95/458.01 [M+H]+; HRMS (+ESI): 456.0417 [M + H]+; Calcd for 
C21H14N3O5SCl: 456.0415. 
 
4-(6-Chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridin-8-yl)phenol (11): 
Compound 11 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 5/3/2) and recrystallization from acetonitrile as a 
yellow solid in 66% yield (0.27 g). mp 267 °C; 1H NMR (400 MHz, [D6]DMSO) δ: 5.30 (s, 
2H), 6.76–6.79 (m, 2H), 7.52–7.55 (m, 2H), 7.61–7.67 (m, 2H), 7.81–7.84 (m, 3H), 7.97 (d, J 
= 1.7 Hz, 1H), 9.28 (d, J = 1.7 Hz, 1H), 9.92 (s, 1H); 13C NMR (100 MHz, [D6]DMSO) δ: 
55.6 (CH2), 115.2 (2CH), 123.4 (C), 123.6 (CH), 124.6 (C), 128.4 (2CH), 128.8 (CH), 129.3 
(2CH), 130.2 (C), 130.9 (2CH), 131.0 (C), 134.0 (CH), 138.7 (C), 139.15 (C), 141.1 (C), 
158.8 (C); MS ESI+ (m/z): 443.86/445.84 [M+H]+; HRMS (+ESI): 444.0412 [M + H]+; Calcd 
for C20H14N3O5SCl: 444.0415. 
 
{4-[6-Chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridin-8-
yl]phenyl}methanol (12): Compound 12 was obtained after purification by chromatography 
(eluent: dichloromethane/cyclohexane/diethyl ether 4.5/4.5/1) and recrystallization from 
acetonitrile as a yellow solid in 54% yield (0.23 g). mp 244 °C; 1H NMR (400 MHz, 
[D6]DMSO) δ: 4.57 (s, 2H), 4.66 (bs, 1H), 5.30 (s, 2H), 7.33–7. 7 (m, 2H), 7.59–7.67 (m, 
4H), 7.81–7.85 (m, 3H), 8.08 (d, J = 1.9 Hz, 1H), 9.35 (d, J = 1.9 Hz, 1H); 13C NMR (100 
MHz, [D6]DMSO) δ: 55.7 (CH2), 62.5 (CH2), 124.4 (C), 124.5 (CH), 126.3 (2CH), 128.4 
(2CH), 129.2 (2CH), 129.3 (2CH), 129.9 (CH), 130.2 (C), 131.0 (C), 131.1 (C), 134.1 (CH), 
138.7 (C), 139.3 (C), 141.2 (C), 144.0 (C); MS ESI+ (m/z): 457.84/459.71 [M+H]+; HRMS 
(+ESI): 458.0571 [M + H]+; Calcd for C21H16N3O5SCl: 458.0572. 
 
{3-[6-Chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridin-8-
yl]phenyl}methanol (13): Compound 13 was obtained after purification by chromatography 
(eluent: dichloromethane/cyclohexane/diethyl ether 6/2/2) and recrystallization from 
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acetonitrile as a yellow solid in 52% yield (0.22 g). mp 210 °C; 1H NMR (400 MHz, 
[D6]DMSO) δ: 4.54 (d, J = 5.3 Hz, 2H), 5.29 (s, 3H), 7.34–7.50 (m, 3H), 7.60–7.66 (m, 3H), 
7.79–7.82 (m, 3H), 8.06 (s, 1H), 9.37 (s, 1H); 13C NMR (100 MHz, [D6]DMSO) δ: 55.8 
(CH2), 62.7 (CH2), 124.4 (C), 124.7 (CH), 127.1 (CH), 127.5 (CH), 128.0 (CH), 128.1 (CH), 
128.3 (2CH), 129.3 (2CH), 130.2 (CH), 130.5 (C), 131.  (C), 132.7 (C), 134.2 (CH), 138.7 
(C), 139.4 (C), 141.2 (C), 143.0 (C); MS ESI+ (m/z): 457.80/459.80 [M+H]+; HRMS (+ESI): 
458.0572 [M + H]+; Calcd for C21H16N3O5SCl: 458.0572. 
 
{2-[6-Chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridin-8-
yl]phenyl}methanol (14): Compound 14 was obtained after purification by chromatography 
(eluent: dichloromethane/cyclohexane/diethyl ether 8/1/1) and recrystallization from propan-
2-ol as a yellow solid in 62% yield (0.26 g). mp 170 °C; 1H NMR (400 MHz, [D6]DMSO) δ: 
4.31 (s, 2H), 5.03 (s, 1H), 5.22 (s, 2H), 7.18–7.20 (m, 1H), 7.31–7.36 (m, 1H), 7.45–7.50 (m, 
1H), 7.54–7.59 (m, 3H), 7.72–7.75 (m, 3H), 7.91 (s, 1H), 9.39 (s, 1H); 13C NMR (100 MHz, 
[D6]DMSO) δ: 55.7 (CH2), 60.9 (CH2), 123.9 (C), 125.0 (CH), 126.5 (CH), 127.8 (CH), 128.1 
(2CH), 128.8 (CH), 129.2 (2CH), 130.4 (CH), 130.8 (CH), 130.9 (C), 131.8 (C), 131.9 (C), 
134.0 (CH), 138.7 (C), 139.4 (C), 140.7 (C), 141.7 (C); MS ESI+ (m/z): 457.93/459.98 
[M+H] +; HRMS (+ESI): 458.0575 [M + H]+; Calcd for C21H16N3O5SCl: 458.0572. 
 
6-Chloro-8-(4-fluorophenyl)-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 
(15): Compound 15 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 5.5/4/0.5) and recrystallization from acetonitrile 
as a yellow solid in 64% yield (0.26 g). mp 211 °C;1H NMR (400 MHz, [D6]DMSO) δ: 5.30 
(s, 2H), 7.27 (t, J = 8.8 Hz, 2H), 7.63–7.72 (m, 4H), 7.81–7.87 (m, 3H), 8.09 (d, J = 1.8 Hz, 
1H), 9.35 (d, J = 1.8 Hz, 1H); 13C NMR (100 MHz, [D6]DMSO) δ: 55.5 (CH2), 115.3 (d, J = 
21.6 Hz, 2CH), 124.4 (C), 124.7 (CH), 128.3 (2CH), 129.0 (C), 129.2 (d, J = 3.1 Hz, C), 
129.3 (2CH), 130.2 (CH), 131.0 (C), 131.6 (d, J = 8.5 Hz, 2CH), 134.1 (CH), 138.6 (C), 
139.3 (C), 141.0 (C), 162.7 (d, J = 247.7 Hz, C); MS ESI+ (m/z): 445.81/447.12 [M+H]+; 
HRMS (+ESI): 446.0372 [M + H]+; Calcd for C20H13N3O4SFCl: 446.0372. 
 
6-Chloro-8-(3-fluorophenyl)-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 
(16): Compound 16 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 6/3.5/0.5) and recrystallization from propan-2-ol 
as a yellow solid in 63% yield (0.26 g). mp 192 °C;1H NMR (400 MHz, [D6]DMSO) δ: 5.30 
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(s, 2H), 7.31 (t, J = 8 Hz, 1H), 7.44–7.63 (m, 5H), 7.75–7.82 (m, 3H), 8.16 (s, 1H), 9.38 (s, 
1H); 13C NMR (100 MHz, [D6]DMSO) δ: 55.6 (CH2), 116.0 (d, J = 3.6 Hz, CH), 116.3 (C), 
124.3 (C), 125.1 (CH), 125.5 (d, J = 2.8 Hz, CH), 128.2 (2CH), 128.6 (d, J = 2.4 Hz, C), 
129.2 (2CH), 130.3 (d, J = 8.4 Hz, CH), 130.6 (CH), 131.1 (C), 134.1 (CH), 134.9 (d, J = 8.6 
Hz, CH), 138.6 (C), 139.3 (C), 140.9 (C), 161.8 (d, J = 243.5 Hz, C); MS ESI+ (m/z): 
445.79/447.14 [M+H]+; HRMS (+ESI): 446.0370 [M + H]+; Calcd for C20H13N3O4SFCl: 
446.0372. 
 
6-Chloro-8-(2-fluorophenyl)-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 
(17): Compound 17 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 4.7/5/0.3) and recrystallization from propan-2-ol 
as a yellow solid in 71% yield (0.29 g). mp 220 °C;1H NMR (400 MHz, [D6]DMSO) δ: 5.26 
(s, 2H), 7.26–7.42 (m, 3H), 7.53–7.61 (m, 3H), 7.76–7.78 (m, 3H), 8.05 (s, 1H), 9.41 (s, 1H); 
13C NMR (100 MHz, [D6]DMSO) δ: 55.7 (CH2), 115.9 (d, J = 21.6 Hz, CH), 120.8 (d, J = 14 
Hz, C), 123.8 (C), 124.3 (d, J = 3.5 Hz, CH), 125.3 (C), 125.6 (CH), 128.2 (2CH), 129.2 
(2CH), 131.1 (C), 131.5 (d, J = 8.5 Hz, CH), 132.2 (d, J = 2.1 Hz, CH), 132.3 (d, J = 2.9 Hz, 
CH), 134.0 (CH), 138.7 (C), 139.5 (C), 141.2 (C), 159.2 (d, J = 248.5 Hz, C); MS ESI+ (m/z): 
445.88/447.14 [M+H]+; HRMS (+ESI): 446.0369 [M + H]+; Calcd for C20H13N3O4SFCl: 
446.0372. 
 
6-Chloro-8-(2,4-difluorophenyl)-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 
(18): Compound 18 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 4.5/5/0.5) and recrystallization from acetonitrile 
as a yellow solid in 61% yield (0.26 g). mp 232 °C;1H NMR (300 MHz, [D6]DMSO) δ: 5.25 
(s, 2H), 7.16–7.23 (td, J = 2.2 Hz and 8.5 Hz, 1H), 7.41–7.50 (m, 2H), 7.57–7.62 (m, 2H), 
7.76–7.81 (m, 3H), 8.06 (s, 1H), 9.41 (d, J = 1.7 Hz, 1H); 13C NMR (75 MHz, [D6]DMSO) δ: 
55.6 (CH2), 104.4 (t, J = 26.5 Hz, CH), 111.5 (dd, J = 3.7 Hz and 21.4 Hz, CH), 117.4 (dd, J 
= 3.7 Hz and 14.3 Hz, C), 123.8 (C), 124.4 (C), 125.7 (CH), 128.2 (2CH), 129.2 (2CH), 131.1 
(C), 132.3 (d, J = 3.3 Hz, CH), 133.4 (dd, J = 3.8 Hz and 10.2 Hz, CH), 134.0 (CH), 139.1 (d, 
J = 62.6 Hz, C), 141.1 (C), 157.9 (d, J = 12.8 Hz, C), 161.2 (d, J = 14.7 Hz, C), 164.5 (d, J = 
12.5 Hz, C); MS ESI+ (m/z): 463.85/465.80 [M+H]+; HRMS (+ESI): 464.0280 [M + H]+; 
Calcd for C20H12N3O4SF2Cl: 464.0278. 
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6-Chloro-3-nitro-2-(phenylsulfonylmethyl)-8-(4-trif luoromethylphenyl)imidazo[1,2-
a]pyridine (19): Compound 19 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 5/4.5/0.5) and recrystallization from propan-2-ol 
as a yellow solid in 87% yield (0.40 g). mp 231 °C;1H NMR (300 MHz, [D6]DMSO) δ: 5.29 
(s, 2H), 7.61–7.67 (m, 2H), 7.75–7.86 (m, 7H), 8.19 (d, J = 1.7 Hz, 1H), 9.40 (d, J = 1.7 Hz, 
1H); 13C NMR (75 MHz, [D6]DMSO) δ: 55.6 (CH2), 124.0 (q, J = 272.4 Hz, CF3), 124.4 (C), 
125.1 (q, J = 3.7 Hz, 2CH), 125.6 (CH), 128.4 (2CH), 128.6 (C), 129.3 (2CH), 129.5 (q, J = 
32 Hz, C), 130.2 (2CH), 131.0 (CH), 131.1 (C), 134. (CH), 136.9 (C), 138.6 (C), 139.5 (C), 
140.9 (C); MS ESI+ (m/z): 495.80/497.91 [M+H]+; HRMS (+ESI): 496.0342 [M + H]+; Calcd 
for C21H13N3O4SF3Cl: 496.0340. 
 
6-Chloro-3-nitro-2-(phenylsulfonylmethyl)-8-(3-trif luoromethylphenyl)imidazo[1,2-
a]pyridine (20): Compound 20 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 5.5/4/0.5) and recrystallization from acetonitrile 
as a yellow solid in 59% yield (0.27 g). mp 182 °C;1H NMR (400 MHz, [D6]DMSO) δ: 5.28 
(s, 2H), 7.32–7.39 (m, 1H), 7.56–7.70 (m, 3H), 7.74–7.86 (m, 3H), 7.93–7.96 (m, 1H), 8.20–
8.27 (m, 2H), 9.41 (s, 1H); 13C NMR (100 MHz, [D6]DMSO) δ: 55.7 (CH2), 124.0 (q, J = 
272.4 Hz, CF3), 124.4 (C), 125.4 (CH), 125.9 (q, J = 3.9 Hz, 2CH), 128.2 (2CH), 128.5 (C), 
129.2 (2CH), 129.3 (CH), 129.4 (q, J = 32 Hz, C), 131.0 (CH), 131.1 (C), 133.6 (CH), 133.9 
(C), 134.1 (CH), 138.7 (C), 139.4 (C), 141.0 (C); MS ESI+ (m/z): 495.82/497.89 [M+H]+; 
HRMS (+ESI): 496.0340 [M + H]+; Calcd for C21H13N3O4SF3Cl: 496.0340. 
 
6-Chloro-3-nitro-2-(phenylsulfonylmethyl)-8-(2-trif luoromethylphenyl)imidazo[1,2-
a]pyridine  (21): Compound 21 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 5/4.5/0.5) and recrystallization from propan-2-ol 
as a yellow solid in 41% yield (0.19 g). mp 189 °C;1H NMR (300 MHz, [D6]DMSO) δ: 5.21 
(s, 2H), 7.37–7.39 (m, 1H), 7.51–7.55 (m, 2H), 7.65–7.67 (m, 2H), 7.70–7.79 (m, 3H), 7.88–
7.89 (m, 1H), 7.92 (s, 1H), 9.44 (s, 1H); 13C NMR (75 MHz, [D6]DMSO) δ: 55.6 (CH2), 
123.4 (C), 123.7 (q, J = 274.3 Hz, CF3), 125.8 (CH), 126.2 (q, J = 4.9 Hz, CH), 127.6 (q, J = 
29.8 Hz, C), 128.3 (2CH), 128.8 (C), 129.0 (2CH), 129.6 (CH), 131.1 (C), 131.7 (d, J = 2.1 
Hz, C), 131.9 (d, J = 1.3 Hz, CH), 132.1 (CH), 132.6 (CH), 134.0 (CH), 138.5 (C), 139.5 (C), 
141.8 (C); MS ESI+ (m/z): 495.78/497.89 [M+H]+; HRMS (+ESI): 496.0341 [M + H]+; Calcd 
for C21H13N3O4SF3Cl: 496.0340. 
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6-Chloro-3-nitro-2-(phenylsulfonylmethyl)-8-(pyridi n-3-yl)imidazo[1,2-a]pyridine (22): 
Compound 22 was obtained after purification by chromatography (eluent: 
dichloromethane/ethyl acetate 9/1) and recrystallization from acetonitrile as a yellow solid in 
53% yield (0.21 g). mp 215 °C; 1H NMR (400 MHz, [D6]DMSO) δ: 5.30 (s, 2H), 7.44–7.50 
(m, 1H), 7.59–7.65 (m, 2H), 7.77–7.83 (m, 3H), 7.99–8.02 (m, 1H), 8.25 (s, 1H), 8.66 (d, J = 
4.5 Hz, 1H), 8.92 (s, 1H), 9.40 (s, 1H); 13C NMR (100 MHz, [D6]DMSO) δ: 55.6 (CH2), 
123.2 (CH), 124.4 (C), 125.4 (CH), 127.2 (C), 128.3 (2CH), 128.9 (C), 129.3 (2CH), 130.6 
(CH), 131.1 (C), 134.2 (CH), 136.8 (CH), 138.6 (C), 139.4 (C), 141.0 (C), 149.6 (CH), 150.1 
(CH); MS ESI+ (m/z): 428.95/430.89 [M+H]+; HRMS (+ESI): 429.0418 [M + H]+; Calcd for 
C19H13N4O4SCl: 429.0419. 
 
6-Chloro-3-nitro-2-(phenylsulfonylmethyl)-8-(pyridi n-4-yl)imidazo[1,2-a]pyridine (23): 
Compound 23 was obtained after purification by chromatography (eluent: 
dichloromethane/ethyl acetate 9/1) and recrystallization from acetonitrile as a yellow solid in 
51% yield (0.20 g). mp 230 °C; 1H NMR (400 MHz, CDCl3) δ: 5.18 (s, 2H), 7.52–7.58 (m, 
2H), 7.67–7.74 (m, 3H), 7.82–7.89 (m, 3H), 8.73 (d, J = 5.5 Hz, 2H), 9.54 (s, 1H); 13C NMR 
(100 MHz, CDCl3) δ: 56.6 (CH2), 123.6 (2CH), 125.7 (C), 126.0 (CH), 128.7 (2CH), 128.8 
(C), 129.4 (2CH), 130.8 (CH), 131.3 (C), 134.3 (CH), 139.4 (C), 139.8 (C), 140.8 (C), 141.2 
(C), 150.3 (2CH); MS ESI+ (m/z): 428.93/430.97 [M+H]+; HRMS (+ESI): 429.0417 [M + 
H]+; Calcd for C19H13N4O4SCl: 429.0419. 
 
6-Chloro-3-nitro-2-(phenylsulfonylmethyl)-8-(thiophen-2-yl)imidazo[1,2-a]pyridine (24): 
Compound 24 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 5.5/4/0.5) as a yellow solid in 60% yield (0.24 g). 
mp 255 °C; 1H NMR (300 MHz, [D6]DMSO) δ: 5.33 (s, 2H), 7.21 (s, 1H), 7.61–7.99 (m, 7H), 
8.30 (s, 1H), 9.26 (s, 1H); 13C NMR (75 MHz, [D6]DMSO) δ: 55.7 (CH2), 123.8 (CH), 123.9 
(C), 124.4 (C), 126.9 (CH), 127.8 (CH), 128.2 (2CH), 129.4 (2CH), 129.7 (CH), 130.6 (CH), 
131.6 (C), 133.8 (C), 134.2 (CH), 138.8 (C), 138.9 (C), 141.1 (C); MS ESI+ (m/z): 
433.81/435.84 [M+H]+; HRMS (+ESI): 434.0050 [M + H]+; Calcd for C18H12ClN3O4S2: 
434.0031. 
 
6-Chloro-8-(furan-2-yl)-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine (25): 
Compound 25 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 4/5.5/0.5) and recrystallization from acetonitrile 
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as a yellow solid in 53% yield (0.21 g). mp 236 °C;1H NMR (400 MHz, [D6]DMSO) δ: 5.34 
(s, 2H), 6.70 (q, J = 1.8 Hz, 1H), 7.10 (d, J = 3.1 Hz, 1H), 7.57–7.62 (m, 2H), 7.75 (tt, J = 1.2 
Hz and 7.5 Hz, 1H), 7.81–7.84 (m, 2H), 7.97 (dd, J = 0.6 Hz and 1.7 Hz, 1H), 8.02 (d, J = 1.9 
Hz, 1H), 9.23 (d, J = 1.9 Hz, 1H); 13C NMR (100 MHz, [D6]DMSO) δ: 55.6 (CH2), 112.7 
(CH), 114.9 (CH), 119.6 (C), 123.7 (CH), 124.2 (C), 124.3 (CH), 128.2 (2CH), 129.2 (2CH), 
131.2 (C), 134.1 (CH), 138.3 (C), 138.8 (C), 139.0 (C), 145.5 (C), 145.6 (CH); MS ESI+ 
(m/z): 417.01/418.25 [M+H]+; HRMS (+ESI): 418.0254 [M + H]+; Calcd for C18H12N3O5SCl: 
418.0259. 
 
Biology 
 
Antileishmanial activity assay on L. infantum axenic amastigotes [32]: L. infantum 
promastigotes in logarithmic phase were centrifuged at 900 G for 10 min. The supernatant 
was removed carefully and replaced by the same volume of RPMI 1640 complete medium at 
pH 5.4 and incubated for 24 h at 24 °C. The acidifie  promastigotes were incubated for 24 h 
at 37 °C in a ventilated flask. Promastigotes were then transformed into amastigotes. The 
effects of the tested compounds on the growth of L. infantum axenic amastigotes were 
assessed as follows. L. infantum amastigotes were incubated at a density of 2.106 
parasites/mL in sterile 96-well plates with various concentrations of compounds dissolved in 
DMSO (final concentration less than 0.5% v/v), in duplicate. Appropriate controls (DMSO, 
amphotericin B, miltefosine and pentamidine) were added to each set of experiments. After a 
48 h incubation period at 37 °C, each plate-well was microscope-examined for detecting any 
precipitate formation. To estimate the luciferase activity of axenic amastigotes, 80 µL of each 
well were transferred to white 96-well plates, Steady Glow® reagent (Promega) was added 
according to manufacturer's instructions, and plates were incubated for 2 min. The 
luminescence was measured in Microbeta Luminescence Counter (PerkinElmer). Inhibitory 
concentration 50% (IC50) was defined as the concentration of drug required to inhibit by 50% 
the metabolic activity of L. infantum amastigotes compared to control. IC50 values were 
calculated by non-linear regression analysis processed on dose-response curves, using 
TableCurve 2D V5 software. IC50 values represent the mean. 
 
Antileishmanial activity assay on L. donovani promastigotes: The effects of the tested 
compounds on the growth of L. donovani promastigotes (MHOM/IN/00/DEVI strain) were 
assessed by MTT assay [33]. Briefly, promastigotes in log-phase in Schneider’s medium 
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supplemented with 20% fœtal calf serum (FCS), 2 mM L-glutamine and antibiotics (100 
U/mL penicillin and 100 µg/mL streptomycin), were incubated at an average density of 106
parasites/mL in sterile 96-well plates with various concentrations of compounds dissolved in 
DMSO (final concentration less than 0.5% v/v), in duplicate. Appropriate controls treated by 
DMSO, miltefosine or amphotericin B (reference drugs purchased from Sigma Aldrich) were 
added to each set of experiments. After a 72 h incubation period at 27 °C, parasite metabolic 
activity was determined. Each plate-well was then microscope-examined for detecting 
possible precipitate formation. 10 µL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) solution (10 mg/mL in PBS) were added to each well followed 
by incubation for another 4 h. The enzyme reaction was then stopped by addition of 100 µL of 
50% isopropanol–10% sodium dodecyl sulfate. The plates were shaken vigorously (300 rpm) 
for 10 min. The absorbance was finally measured at 570 nm in a BIO-TEK ELx808 
Absorbance Microplate Reader. Inhibitory concentration 50% (IC50) was defined as the 
concentration of drug required to inhibit by 50% the metabolic activity of L. donovani and 
promastigotes compared to the control. IC50 were calculated by nonlinear regression analysis 
processed on dose–response curves, using TableCurve 2D V5.0 software. IC50 values 
represent the mean value calculated from three independent experiments. 
 
Antileishmanial activity assay on L. donovani intramacrophage amastigotes: The effects 
of the tested compounds on the growth of Leishmania donovani amastigotes were assessed 
according to the method of da Luz et al. [34]. 400 µL of THP-1 cells with Phorbol 12-
Myristate 13-Acetate (final concentration: 50 ng/mL) were seeded in sterile chamber-slides at 
an average density of 105 cells/mL and incubated for 48 h at 37 °C and 6% CO2. L. donovani 
promastigotes were centrifuged at 900 G for 10 min and the supernatant was replaced by the 
same volume of Schneider 20% FCS pH 5.4 and incubated for 24 h at 27 °C. THP-1 cells 
were then infected by acidified promastigotes at an average density of 106 cells/mL (10:1 
ratio) and chamber-slides were incubated for 24 h at 37 °C. Then, in duplicate, the medium 
containing various concentrations of tested compounds was added (final DMSO concentration 
below 0.5% v/v). Appropriate controls treated with or without solvent (DMSO), and various 
concentrations of miltefosine and amphotericin B were added to each set of experiments. 
After a 120 h incubation at 37 °C and 6% CO2, the well supernatant was removed. Cells were 
fixed with analytical grade methanol and stained with 10% Giemsa. The percentage of 
infected macrophages in each assay was determined microscopically by counting at least 200 
cells in each sample. IC50 was defined as the concentration of drug necessary to produce a 
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50% decrease in infected macrophages compared to the control. IC50 were calculated by non-
linear regression analysis processed on dose–response curves, using TableCurve 2D V5.0 
software. IC50 values represent the mean value calculated from three independent 
experiments. 
 
Antitrypanosomal activity assay on trypomastigotes: The effects of the tested compounds 
on the growth of T. brucei brucei were assessed by Alamar Blue® assay described by Räz et 
al. [35] Trypanosoma brucei brucei AnTat 1.9 (IMTA, Antwerpen, Belgium) was cultured in 
MEM with Earle’s salts, supplemented according to the protocol of Baltz et al. [36] with the 
following modifications: 0.5 mM Mercaptoethanol (Sigma Aldrich®, France), 1.5 mM L-
cysteine (Sigma Aldrich®), 0.05 mM Bathocuproïne sulfate (Sigma Aldrich®) and 20% heat-
inactivated horse serum (Gibco®, France), at 37 °C and 5% CO2. They were incubated at an 
average density of 2000 parasites/100µL in sterile 96-well plates (Fisher®, France) with 
various concentrations of compounds dissolved in DMSO, in duplicate. Appropriate controls 
treated by DMSO on sterile water, suramin, eflornithi e and fexinidazole (reference drugs 
purchased from Sigma Aldrich, France and Fluorochem, UK) were added to each set of 
experiments. After a 69 h incubation period at 37 °C, 10 µL of the viability marker Alamar 
Blue® (Fisher, France) was then added to each well, and the plates were incubated for 5 h. 
The plates were read in a PerkinElmer ENSPIRE (Germany) microplate reader using an 
excitation wavelength of 530 nm and an emission wavelength of 590 nm. IC50 was defined as 
the concentration of drug necessary to inhibit by 50% the activity of T. brucei brucei 
compared to the control. IC50 were calculated by nonlinear regression analysis processed on 
dose-response curves, using GraphPad Prism software (USA). IC50 values were calculated 
from three independent experiments. 
 
Cytotoxicity assay on HepG2 cell line: The evaluation of the tested molecules cytotoxicity 
on the HepG2 cell line (hepatocarcinoma cell line purchased from ATCC, ref H-8065) was 
performed according to the method of Mosman [33] with slight modifications. Briefly, cells in 
100 µL of complete RPMI medium, [RPMI supplemented with 10% FCS, 1% L-glutamine 
(200 mM) and penicillin (100 U/mL)/streptomycin (100 µg/mL)] were inoculated into each 
well of 96-well plates and incubated at 37 °C in a humidified 6% CO2. After a 24 h 
incubation, 100 µL of medium with various product con entrations dissolved in DMSO (final 
concentration less than 0.5% v/v) were added and the plates were incubated for 72 h at 37 °C. 
Duplicate assays were performed for each sample. Each plate-well was then microscope-
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examined for detecting possible precipitate formation before the medium was aspirated from 
the wells. 100 µL of MTT solution (0.5 mg/mL in medium without FCS) were then added to 
each well. Cells were incubated for 2 h at 37 °C. After this time, the MTT solution was 
removed and DMSO (100 µL) was added to dissolve the resulting blue formazan crystals. 
Plates were shaken vigorously (300 rpm) for 5 min. The absorbance was measured at 570 nm 
with 630 nm as reference wavelength spectrophotometer using a BIO-TEK ELx808 
Absorbance Microplate Reader. DMSO was used as blank and doxorubicin (purchased from 
Sigma Aldrich) as positive control. Cell viability was calculated as percentage of control 
(cells incubated without compound). The 50% cytotoxic concentration was determined from 
the dose–response curve by using the TableCurve 2D V5.0 software. 
 
Cytotoxicity assay on THP1 cell line: The evaluation of the tested molecules cytotoxicity on 
the differentiated THP1 cell line (acute monocyte leukemia cell line purchased from ATCC, 
ref TIB-202) was performed according to the method f Mosman [33] with slight 
modifications. Briefly, cells in 100 µL of complete RPMI medium with Phorbol 12-myristate 
13-acetate (final concentration: 50 ng/mL) were incubated at an average density of 106 
cells/mL and in sterile 96-well plates. After a 48 h incubation, 100 µL of medium with 
various product concentrations dissolved in DMSO (final concentration less than 0.5% v/v) 
were added and the plates were incubated for 72 h at 37 °C. Each plate-well was then 
microscope-examined for detecting possible precipitate formation before the medium was 
aspirated from the wells. 100 µL of MTT solution (0.5 mg/mL in medium without FCS) were 
then added to each well. Cells were incubated for 2 h at 37 °C. After this time, the MTT 
solution was removed and DMSO (100 µL) was added to dissolve the resulting blue formazan 
crystals. Plates were shaken vigorously (300 rpm) for 10 min. The absorbance was measured 
at 570 nm with 630 nm as reference wavelength spectrophotometer using a BIO-TEK ELx808 
Absorbance Microplate Reader. DMSO was used as blank and doxorubicin (purchased from 
Sigma Aldrich) as positive control. Cell viability was calculated as percentage of control 
(cells incubated without compound). The 50% cytotoxic concentration was determined from 
the dose–response curve by using the TableCurve 2D V5.0 software. 
 
Metabolism of 13 and 23 in L. donovani promastigotes: The clonal Leishmania donovani 
cell line LdBOB (derived from MHOM/SD/62/1S-CL2D) was grown as promastigotes at 26 
°C in modified M199 media, as previously described [37]. LdBOB promastigotes 
overexpressing NTR1 (LinJ.05.0660) [19] and NTR2 (LinJ.12.0730) [20] were grown in the 
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presence of nourseothricin (100 µg.mL−1). Then to examine the effects of test compounds on 
growth, triplicate promastigote cultures were seeded with 5 × 104 parasites.mL-1. Parasites 
were grown in 10 mL cultures in the presence of drug for 72 h, after which 200 µL aliquots of 
each culture were added to 96-well plates, 50 µM resazurin was added to each well and 
fluorescence (excitation of 528 nm and emission of 590 nm) measured after a further 4 h 
incubation [14]. Data were processed using GRAFIT (version 5.0.4; Erithacus software) and 
fitted to a 2-parameter equation, where the data are co rected for background fluorescence, to 
obtain the effective concentration inhibiting growth by 50% (EC50): 
y = 	 100
1 +  I
EC
 
In this equation [I] represents inhibitor concentration and m is the slope factor. Experiments 
were repeated at least two times and the data is presented as the mean plus standard deviation. 
 
Metabolism of 14 and 20 in T. brucei: Trypanosoma brucei bloodstream-form 'single 
marker' S427 (T7RPOL TETR NEO) and drug-resistant cell lines were cultured at 37°C in 
HMI9-T medium [38] supplemented with 2.5 µg.mL−1 G418 to maintain expression of T7 
RNA polymerase and the tetracycline repressor protein. Bloodstream trypanosomes 
overexpressing the T. brucei nitroreductase (NTR1) [21] were grown in medium 
supplemented with 2.5 µg.mL−1 phleomycin and expression of NTR was induced by the 
addition of 1 µg.mL−1 tetracycline. Cultures were initiated with 1 × 105 cells.mL−1 and sub-
cultured when cell densities approached 1–2 (× 106).mL−1. 
In order to examine the effects of inhibitors on the growth of these parasites, triplicate 
cultures containing the inhibitor were seeded at 1 × 105 trypanosomes.mL-1. Cells 
overexpressing NTR were induced with tetracycline 48 h prior to EC50 analysis. Cell densities 
were determined after culture for 72 h, as previously described [39]. EC50 values were 
determined using the following two-parameter equation by non-linear regression using 
GraFit:  
where the experimental data were corrected for background cell density and expressed as a 
percentage of the uninhibited control cell density.  
m
EC
I
y






+
=
50
][
1
100  
In this equation [I] represents inhibitor concentration and m is the slope factor. 
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Highlights: 
A Suzuki-Miyaura reaction at position 8 of the imidazopyridine ring was studied 
21 derivatives were tested in vitro for their cytotoxicity and antiparasitic activity 
7 antileishmanial and 8 antitrypanosomal hit compounds were identified 
These nitroaromatic derivatives are bioactivated by type 1 nitroreductases 
 
